Free Trial
NASDAQ:DWTX

Dogwood Therapeutics Q1 2025 Earnings Report

Dogwood Therapeutics logo
$4.65 -0.34 (-6.81%)
Closing price 08/27/2025 03:59 PM Eastern
Extended Trading
$4.84 +0.19 (+4.09%)
As of 08/27/2025 07:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Dogwood Therapeutics EPS Results

Actual EPS
-$4.21
Consensus EPS
-$0.77
Beat/Miss
Missed by -$3.44
One Year Ago EPS
N/A

Dogwood Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Dogwood Therapeutics Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Thursday, May 8, 2025
Conference Call Time
9:00AM ET

Upcoming Earnings

Dogwood Therapeutics' Q3 2025 earnings is scheduled for Thursday, November 6, 2025, with a conference call scheduled at 8:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Dogwood Therapeutics Earnings Headlines

HC Wainwright Has Optimistic Outlook of DWTX Q3 Earnings
HC Wainwright Issues Pessimistic Outlook for DWTX Earnings
Breaking News: Trump Could Unlock $21 Trillion for Everyday Americans
President Trump just signed a new law… That could unlock $21 trillion for everyday folks like you… And potentially impact every checking and savings account in America.tc pixel
See More Dogwood Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Dogwood Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Dogwood Therapeutics and other key companies, straight to your email.

About Dogwood Therapeutics

Dogwood Therapeutics (NASDAQ:DWTX). is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia. The company was founded on February 28, 2012 is headquartered in Alpharetta, GA.

View Dogwood Therapeutics Profile

More Earnings Resources from MarketBeat